191 related articles for article (PubMed ID: 10759957)
1. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Thewes M; Elsner E; Wessner D; Engst R; Ring J
Int J Dermatol; 2000 Mar; 39(3):188-91. PubMed ID: 10759957
[TBL] [Abstract][Full Text] [Related]
2. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
3. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Ulisse S; Baldini E; Mottolese M; Sentinelli S; Gargiulo P; Valentina B; Sorrenti S; Di Benedetto A; De Antoni E; D'Armiento M
BMC Cancer; 2010 Apr; 10():151. PubMed ID: 20403162
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract][Full Text] [Related]
8. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
10. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
[TBL] [Abstract][Full Text] [Related]
11. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E
Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P
Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
[TBL] [Abstract][Full Text] [Related]
16. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
He C; He P; Liu LP; Zhu YS
J Cancer Res Clin Oncol; 2001; 127(3):180-6. PubMed ID: 11260863
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals.
Herndier BG; Werner A; Arnstein P; Abbey NW; Demartis F; Cohen RL; Shuman MA; Levy JA
AIDS; 1994 May; 8(5):575-81. PubMed ID: 7520247
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
